Jing Wang

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Randomized Controlled Trial

Mesenchymal Stem Cells

Dna Damage Response

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Research (Washington, D.C.)

Journal of translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Nayiyuan Wu, Xiu Zhang, Chao Fang, Miaochen Zhu, Zhibin Wang, Lian Jian, Weili Tan, Ying Wang, He Li, Xuemeng Xu, Yujuan Zhou, Tang-Yuan Chu, Jing Wang, Qianjin Liao
Progesterone Enhances Niraparib Efficacy in Ovarian Cancer by Promoting Palmitoleic-Acid-Mediated Ferroptosis. Research (Washington, D.C.) 7 (2024)
Zhi-Bin Wang, Xiu Zhang, Chao Fang, Xiao-Ting Liu, Qian-Jin Liao, Nayiyuan Wu, Jing Wang
Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology (2024)
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Nayiyuan Wu, Xiu Zhang, Chao Fang, Miaochen Zhu, Zhibin Wang, Lian Jian, Weili Tan, Ying Wang, He Li, Xuemeng Xu, Yujuan Zhou, Tang-Yuan Chu, Jing Wang, Qianjin Liao
Progesterone Enhances Niraparib Efficacy in Ovarian Cancer by Promoting Palmitoleic-Acid-Mediated Ferroptosis. Research (Washington, D.C.) 7 (2024)
Fen Xiao, ZhiBin Wang, Liu Qiao, Xiu Zhang, NaYiYuan Wu, Jing Wang, Xing Yu
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer. Journal of translational medicine 22 (1) (2024)
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (8) (2024)
Fen Xiao, ZhiBin Wang, Liu Qiao, Xiu Zhang, NaYiYuan Wu, Jing Wang, Xing Yu
Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer. Journal of translational medicine 22 (1) (2024)
Zhi-Bin Wang, Xiu Zhang, Chao Fang, Xiao-Ting Liu, Qian-Jin Liao, Nayiyuan Wu, Jing Wang
Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology 173 (1) (2024)
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Wenjing Qin, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jing Wang
Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
He Li, Zhao-Yi Liu, Nayiyuan Wu, Yong-Chang Chen, Quan Cheng, Jing Wang
PARP inhibitor resistance: the underlying mechanisms and clinical implications. Molecular cancer 19 (1) (2020)